Drug Innovation
Coronavirus
NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Commentary
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Commentary
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Commentary
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Commentary
Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine
By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
Commentary
Read the latest on Florida's drug importation plan
Is the FDA opening a door for counterfeit drug trade?
The U.S. Food and Drug Administration gave the go-ahead last month for Florida to import prescription drugs in bulk from Canada. If all goes according to plan, the state government will be able to dispense certain Canadian-sourced drugs to people who receive care through the state Department of Corrections, the ...
Commentary
Read the latest on prescription drug pricing
Bernie’s Anti-Pharma Crusade Is Not In Patients’ Interests
Next week, the Senate Health, Education, Labor, and Pensions Committee will convene to hear testimony from the CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb on the prices of their drugs. The executives agreed to testify after the committee’s chair, Vermont socialist Sen. Bernie Sanders, I-Vt., threatened to ...
Commentary
Read the latest on Florida's drug importation plan
Fla’s Drug Importation Plan Only Creates More Problems
The logic behind Florida’s new drug-importation program, which the U.S. Food and Drug Administration formally approved earlier this month, might seem straightforward. Since prescription drugs cost less in Canada, purchasing medicines in bulk from across our northern border should deliver significant savings. As Florida will soon discover, however, the devil is ...
Commentary
Read Sally Pipes' latest at Forbes
Florida’s Drug Importation Plan Is A Bipartisan Blunder
It’s not every day that President Joe Biden and Florida Gov. Ron DeSantis agree. But that’s exactly what happened this month, when the U.S. Food and Drug Administration green-lit Florida’s request to import certain prescription drugs from Canada, where they’re cheaper. “Canada has the same drugs. They’re like 25 cents on the ...
Blog
Read how Biden plan would hurt medical innovation
The Biden Administration Abuses Inflation to Attack Medical Innovation
It is theoretically bankrupt because price changes for individual goods and services reflect unique market factors in addition to broad-based inflation trends. There is no reason to expect any good’s price changes to always equal the average of all price changes (e.g., measured inflation). For instance, a deep frost that ...
NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine
By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
Read the latest on Florida's drug importation plan
Is the FDA opening a door for counterfeit drug trade?
The U.S. Food and Drug Administration gave the go-ahead last month for Florida to import prescription drugs in bulk from Canada. If all goes according to plan, the state government will be able to dispense certain Canadian-sourced drugs to people who receive care through the state Department of Corrections, the ...
Read the latest on prescription drug pricing
Bernie’s Anti-Pharma Crusade Is Not In Patients’ Interests
Next week, the Senate Health, Education, Labor, and Pensions Committee will convene to hear testimony from the CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb on the prices of their drugs. The executives agreed to testify after the committee’s chair, Vermont socialist Sen. Bernie Sanders, I-Vt., threatened to ...
Read the latest on Florida's drug importation plan
Fla’s Drug Importation Plan Only Creates More Problems
The logic behind Florida’s new drug-importation program, which the U.S. Food and Drug Administration formally approved earlier this month, might seem straightforward. Since prescription drugs cost less in Canada, purchasing medicines in bulk from across our northern border should deliver significant savings. As Florida will soon discover, however, the devil is ...
Read Sally Pipes' latest at Forbes
Florida’s Drug Importation Plan Is A Bipartisan Blunder
It’s not every day that President Joe Biden and Florida Gov. Ron DeSantis agree. But that’s exactly what happened this month, when the U.S. Food and Drug Administration green-lit Florida’s request to import certain prescription drugs from Canada, where they’re cheaper. “Canada has the same drugs. They’re like 25 cents on the ...
Read how Biden plan would hurt medical innovation
The Biden Administration Abuses Inflation to Attack Medical Innovation
It is theoretically bankrupt because price changes for individual goods and services reflect unique market factors in addition to broad-based inflation trends. There is no reason to expect any good’s price changes to always equal the average of all price changes (e.g., measured inflation). For instance, a deep frost that ...
